> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Discuss Spectrum Pharma NDA
- URL: https://www.fdaweb.com/panel-to-discuss-spectrum-pharma-nda/
- Published: 2016-07-28T12:00:00.000Z
- Updated: 2026-09-14T21:19:18.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5136324

*Federal Register* Notice: FDA will hold a meeting of the Oncologic Drugs Advisory Committee 9/14, from 8 a.m. to 1 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The committee will discuss a Spectrum Pharmaceuticals NDA for apaziquone for intravesical instillation. The proposed indication is for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. Contact **Lauren D. Tesh**, (301) 796-9001\. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-07-28/pdf/2016-17865.pdf?ref=fdaweb.com)